Keywords: GlaxoSmithKline, Impax Pharma, IPX066, Parkinson's disease
Strong Ph III data for GlaxoSmithKline/Impax Parkinson’s drug
Article | 16 March 2011
UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday announced positive, top-line results of the ADVANCE-Parkinson’s Disease Phase III clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
